Quarterly report [Sections 13 or 15(d)]

Restructuring (Details)

Restructuring (Details) $ in Thousands	3 Months Ended					9 Months Ended			12 Months Ended
Restructuring (Details) $ in Thousands	Mar. 31, 2026 USD ($)	Sep. 30, 2025 USD ($) installment	Jun. 30, 2025 USD ($)	Mar. 31, 2025 USD ($)	Sep. 30, 2024 USD ($)	Mar. 31, 2026 USD ($)	Jun. 30, 2025 USD ($)	Mar. 31, 2025 USD ($)	Jun. 30, 2025 USD ($)
Restructuring
Recovery of assets held-for-sale						$ 6,789		$ 3,655
Fair Value, Recurring \| Other Noncurrent Assets
Restructuring
Notes receivable	$ 8,119		$ 2,184			8,119	$ 2,184		$ 2,184
Restructuring Plan to Optimize Global Manufacturing
Restructuring
Restructuring costs	2,836		95,631			6,257
Cash payments						(12,966)
Non-cash adjustments			(94,530)			6,789
Restructuring reserve, end of period	1,181		1,101			1,181	1,101		1,101
Restructuring Plan to Recover Operating Margins
Restructuring
Restructuring costs	$ 116			$ 420	$ 10,269	$ 1,155	4,148	13,653
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Goods and Services Sold					Cost of Goods and Services Sold
Cash payments						$ (2,053)			(3,354)
Non-cash adjustments									(9,841)
Restructuring reserve, end of period	$ 324		1,222			324	1,222		1,222
Protein Sciences \| Restructuring Plan to Optimize Global Manufacturing
Restructuring
Restructuring costs	2,121					8,224
Protein Sciences \| Restructuring Plan to Recover Operating Margins
Restructuring
Restructuring costs	116			129		1,155		12,614
Diagnostics and Spatial Biology \| Restructuring Plan to Optimize Global Manufacturing
Restructuring
Restructuring costs	27					(3,796)
Diagnostics and Spatial Biology \| Restructuring Plan to Recover Operating Margins
Restructuring
Restructuring costs								425
Exosome Diagnostics \| Restructuring Plan to Optimize Global Manufacturing \| Fair Value, Recurring
Restructuring
Notes receivable	9,000					9,000
Exosome Diagnostics \| Disposed of by Sale \| Restructuring Plan to Optimize Global Manufacturing
Restructuring
Consideration for sale		$ 15,000
Consideration as stock		6,800
Recovery of assets held-for-sale		$ 6,800
No. of installments \| installment		4
Installment amount		$ 2,500
Stock consideration receivable		$ 5,000
Exosome Diagnostics \| Held for sale
Restructuring
Cumulative impairment charge			83,100
Exosome Diagnostics \| Held for sale \| Restructuring Plan to Optimize Global Manufacturing
Restructuring
Goodwill attributable to disposal group held for sale			4,500				4,500		4,500
Corporate \| Restructuring Plan to Optimize Global Manufacturing
Restructuring
Restructuring costs	688					1,829
Corporate \| Restructuring Plan to Recover Operating Margins
Restructuring
Restructuring costs				291				614
Cost of Sales \| Restructuring Plan to Optimize Global Manufacturing
Restructuring
Restructuring costs	1,036					3,990
Cost of Sales \| Restructuring Plan to Recover Operating Margins
Restructuring
Restructuring costs				137				7,726
Selling, General and Administrative Expenses \| Restructuring Plan to Optimize Global Manufacturing
Restructuring
Restructuring costs	1,800					2,267
Selling, General and Administrative Expenses \| Restructuring Plan to Recover Operating Margins
Restructuring
Restructuring costs				283				5,927
Employee severance \| Restructuring Plan to Optimize Global Manufacturing
Restructuring
Restructuring costs	1,037		1,041			6,657
Cash payments						(6,517)
Restructuring reserve, end of period	1,181		1,041			1,181	1,041		1,041
Employee severance \| Restructuring Plan to Recover Operating Margins
Restructuring
Restructuring costs	71			301	2,852	769	593	3,358
Cash payments						(1,667)			(2,223)
Restructuring reserve, end of period	324		1,222			324	1,222		1,222
Employee severance \| Protein Sciences \| Restructuring Plan to Optimize Global Manufacturing
Restructuring
Restructuring costs	556					2,374
Employee severance \| Protein Sciences \| Restructuring Plan to Recover Operating Margins
Restructuring
Restructuring costs	71			10		769		2,323
Employee severance \| Diagnostics and Spatial Biology \| Restructuring Plan to Optimize Global Manufacturing
Restructuring
Restructuring costs	27					2,993
Employee severance \| Diagnostics and Spatial Biology \| Restructuring Plan to Recover Operating Margins
Restructuring
Restructuring costs								425
Employee severance \| Corporate \| Restructuring Plan to Optimize Global Manufacturing
Restructuring
Restructuring costs	454					1,290
Employee severance \| Corporate \| Restructuring Plan to Recover Operating Margins
Restructuring
Restructuring costs				291				610
Asset-related and other \| Restructuring Plan to Optimize Global Manufacturing
Restructuring
Restructuring costs	1,799		11,531			6,389
Cash payments						(6,449)
Non-cash adjustments			(11,471)
Restructuring reserve, end of period			60				60		60
Asset-related and other \| Restructuring Plan to Recover Operating Margins
Restructuring
Restructuring costs	45			119	$ 7,417	386	$ 3,555	10,295
Cash payments						(386)			(1,131)
Non-cash adjustments									$ (9,841)
Asset-related and other \| Protein Sciences \| Restructuring Plan to Optimize Global Manufacturing
Restructuring
Restructuring costs	1,565					5,850
Asset-related and other \| Protein Sciences \| Restructuring Plan to Recover Operating Margins
Restructuring
Restructuring costs	45			$ 119		386		10,291
Asset-related and other \| Corporate \| Restructuring Plan to Optimize Global Manufacturing
Restructuring
Restructuring costs	$ 234					539
Asset-related and other \| Corporate \| Restructuring Plan to Recover Operating Margins
Restructuring
Restructuring costs								$ 4
Impairment (Recovery) of assets held-for-sale \| Restructuring Plan to Optimize Global Manufacturing
Restructuring
Restructuring costs			83,059			(6,789)
Non-cash adjustments			$ (83,059)			6,789
Impairment (Recovery) of assets held-for-sale \| Diagnostics and Spatial Biology \| Restructuring Plan to Optimize Global Manufacturing
Restructuring
Restructuring costs						$ (6,789)